

4 February, 2021

Name of listed company: Chugai Pharmaceutical Co., Ltd.
Code number: 4519 (1st Section of Tokyo Stock Exchange)
Head office: 1-1, Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo
Chairman & CEO: Tatsuro Kosaka
Inquiries to: Toshiya Sasai
Head of Corporate Communications Dept.
Tel: +81-(0)3-3273-0554

Notice Regarding the Difference of Individual Financial Results as Compared to Actual Results for the Previous Year

TOKYO, February 4, 2021-- [Chugai Pharmaceutical Co., Ltd.](#) announced that there is a difference regarding the individual financial results (Japanese standard) for the year ended December 2020 (Jan. 1, 2020– Dec. 31, 2020) as compared to the actual results for the previous year (Jan. 1, 2019 – Dec. 31, 2019).

1. Difference between the actual results for the year ended December 2020 and the actual results for the previous year

	Revenues	Operating Income	Ordinary Income	Net Income	Earnings per Share*
Actual results for the previous year (A) (Jan. 1, 2019 – Dec. 31, 2019)	(millions of yen) 678,591	(millions of yen) 203,921	(millions of yen) 208,296	(millions of yen) 155,584	(Yen Sen) 94.74
Actual results for this year (B) (Jan. 1, 2020 – Dec. 31, 2020)	(millions of yen) 779,194	(millions of yen) 288,109	(millions of yen) 290,823	(millions of yen) 207,795	(Yen Sen) 126.44
Change (B-A)	(millions of yen) 100,603	(millions of yen) 84,188	(millions of yen) 82,527	(millions of yen) 52,211	-
Change (%)	14.8	41.3	39.6	33.6	-

*Effective July 1, 2020, Chugai has implemented a three-for-one stock split of its common stock. “Earnings per share” are calculated based on the assumption that the stock split was implemented at the beginning of the previous year.

2. Reasons for the difference occurring

The difference occurred mainly due to increase in exports to Roche, increase in royalties and other operating income, and improvement in cost to sales ratio due to changes in product mix, etc.

###